{
    "abstract": "Background: A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL\u00ae) was tested for its potential effect on the immunogenicity of concomitantly administered EPI vaccines in infants in a randomized controlled study in India. Methods: In this Phase III, multicenter, open label, randomized, controlled study, three doses of BRV-PV or two doses of Rotarix\u00ae and one dose of placebo were given to healthy infants at 6, 10, and 14 weeks of age. Subjects also received three doses of DTwP-HepB-Hib (diphtheria, tetanus, whole-cell pertussis, hepatitis B, and haemophilus influenzae type b conjugate \u2013 pentavalent vaccine) and oral polio vaccine concomitantly at 6, 10, and 14 weeks of age and a single dose of inactivated polio vaccine at 14 weeks of age. Blood samples were collected four weeks after the final vaccination to assess immune responses to all the vaccines administered. For diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 antibodies, non-interference was to be supported if the lower limit of the two-sided 90% confidence interval (CI) for the seroprotection rate difference for the BRV-PV group minus the Rotarix\u00ae group was >10.0%. For pertussis antibodies, non-interference was to be supported if the lower limit of the two-sided 90% CI for the ratio of geometric mean concentrations (GMCs) was >0.5. Results: A total of 1500 infants were randomized to either BRV-PV (1125 infants) or Rotarix\u00ae (375 infants), of which 1341 completed the study as per the protocol. More than 97% of subjects achieved seroprotective antibody titres against diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 in both groups. The difference in seroprotection rates between the BRV-PV group and the Rotarix\u00ae group for all these antibodies was less than 1%. The ratio of GMCs of anti-pertussis IgG concentrations for the BRV-PV group versus Rotarix\u00ae was 1.04 [90% CI: 0.90; 1.19]. Conclusion: BRV-PV does not interfere with the immunogenicity of concomitantly administered routine infants vaccines.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Jacqueline E.",
                    "initial": "J.E.",
                    "last": "Tate"
                },
                {
                    "first": "Anthony H.",
                    "initial": "A.H.",
                    "last": "Burton"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Boschi-Pinto"
                },
                {
                    "first": "Umesh D.",
                    "initial": "U.D.",
                    "last": "Parashar"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Agocs"
                },
                {
                    "first": "Fatima",
                    "initial": "F.",
                    "last": "Serhan"
                },
                {
                    "first": "Lucia",
                    "initial": "L.",
                    "last": "De Oliveira"
                },
                {
                    "first": "Jason M.",
                    "initial": "J.M.",
                    "last": "Mwenda"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mihigo"
                },
                {
                    "first": "Pushpa",
                    "initial": "P.",
                    "last": "Ranjan Wijesinghe"
                },
                {
                    "first": "Nihal",
                    "initial": "N.",
                    "last": "Abeysinghe"
                },
                {
                    "first": "Kimberley",
                    "initial": "K.",
                    "last": "Fox"
                },
                {
                    "first": "Fem",
                    "initial": "F.",
                    "last": "Paladin"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/cid/civ1013",
            "firstpage": "S96",
            "issn": "10584838",
            "lastpage": "S105",
            "pmid": "27059362",
            "pub_year": 2016,
            "title": "Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013",
            "volume": "62"
        },
        "b0010": null,
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "Jagdish K.",
                    "initial": "J.K.",
                    "last": "Zade"
                },
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Sajjad A.",
                    "initial": "S.A.",
                    "last": "Desai"
                },
                {
                    "first": "Rajendra N.",
                    "initial": "R.N.",
                    "last": "Sabale"
                },
                {
                    "first": "Sameer P.",
                    "initial": "S.P.",
                    "last": "Naik"
                },
                {
                    "first": "Rajeev M.",
                    "initial": "R.M.",
                    "last": "Dhere"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.03.003",
            "firstpage": "A124",
            "issn": "0264410X",
            "lastpage": "A128",
            "pmid": "25091665",
            "pub_year": 2014,
            "title": "Bovine rotavirus pentavalent vaccine development in India",
            "volume": "32"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Sameer P.",
                    "initial": "S.P.",
                    "last": "Naik"
                },
                {
                    "first": "Jagdish K.",
                    "initial": "J.K.",
                    "last": "Zade"
                },
                {
                    "first": "Rajendra N.",
                    "initial": "R.N.",
                    "last": "Sabale"
                },
                {
                    "first": "Sambhaji S.",
                    "initial": "S.S.",
                    "last": "Pisal"
                },
                {
                    "first": "Ravi",
                    "initial": "R.",
                    "last": "Menon"
                },
                {
                    "first": "Subhash G.",
                    "initial": "S.G.",
                    "last": "Bankar"
                },
                {
                    "first": "Sunil",
                    "initial": "S.",
                    "last": "Gairola"
                },
                {
                    "first": "Rajeev M.",
                    "initial": "R.M.",
                    "last": "Dhere"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.04.025",
            "firstpage": "2962",
            "issn": "0264410X",
            "lastpage": "2969",
            "pmid": "28434688",
            "pub_year": 2017,
            "title": "Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL\u00ae)",
            "volume": "35"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Sheila",
                    "initial": "S.",
                    "last": "Isanaka"
                },
                {
                    "first": "Ousmane",
                    "initial": "O.",
                    "last": "Guindo"
                },
                {
                    "first": "Celine",
                    "initial": "C.",
                    "last": "Langendorf"
                },
                {
                    "first": "Amadou Matar",
                    "initial": "A.M.",
                    "last": "Seck"
                },
                {
                    "first": "Brian D.",
                    "initial": "B.D.",
                    "last": "Plikaytis"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Sayinzoga-Makombe"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "McNeal"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Meyer"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Adehossi"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Djibo"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Jochum"
                },
                {
                    "first": "Rebecca F.",
                    "initial": "R.F.",
                    "last": "Grais"
                }
            ],
            "doi": "10.1056/NEJMoa1609462",
            "firstpage": "1121",
            "issn": "00284793",
            "lastpage": "1130",
            "pmid": "28328346",
            "pub_year": 2017,
            "title": "Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger",
            "volume": "376"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Sajjad",
                    "initial": "S.",
                    "last": "Desai"
                },
                {
                    "first": "Tushar",
                    "initial": "T.",
                    "last": "Tewari"
                },
                {
                    "first": "Anand",
                    "initial": "A.",
                    "last": "Kawade"
                },
                {
                    "first": "Nidhi",
                    "initial": "N.",
                    "last": "Goyal"
                },
                {
                    "first": "Bishan Swarup",
                    "initial": "B.S.",
                    "last": "Garg"
                },
                {
                    "first": "Dinesh",
                    "initial": "D.",
                    "last": "Kumar"
                },
                {
                    "first": "Suman",
                    "initial": "S.",
                    "last": "Kanungo"
                },
                {
                    "first": "Veena",
                    "initial": "V.",
                    "last": "Kamat"
                },
                {
                    "first": "Gagandeep",
                    "initial": "G.",
                    "last": "Kang"
                },
                {
                    "first": "Ashish",
                    "initial": "A.",
                    "last": "Bavdekar"
                },
                {
                    "first": "Sudhir",
                    "initial": "S.",
                    "last": "Babji"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Juvekar"
                },
                {
                    "first": "Byomkesh",
                    "initial": "B.",
                    "last": "Manna"
                },
                {
                    "first": "Shanta",
                    "initial": "S.",
                    "last": "Dutta"
                },
                {
                    "first": "Rama",
                    "initial": "R.",
                    "last": "Angurana"
                },
                {
                    "first": "Deepika",
                    "initial": "D.",
                    "last": "Dewan"
                },
                {
                    "first": "Abhijeet",
                    "initial": "A.",
                    "last": "Dharmadhikari"
                },
                {
                    "first": "Jagdish K.",
                    "initial": "J.K.",
                    "last": "Zade"
                },
                {
                    "first": "Rajeev M.",
                    "initial": "R.M.",
                    "last": "Dhere"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Fix"
                },
                {
                    "first": "Maureen",
                    "initial": "M.",
                    "last": "Power"
                },
                {
                    "first": "Vidyasagar",
                    "initial": "V.",
                    "last": "Uprety"
                },
                {
                    "first": "Varsha",
                    "initial": "V.",
                    "last": "Parulekar"
                },
                {
                    "first": "Iksung",
                    "initial": "I.",
                    "last": "Cho"
                },
                {
                    "first": "Temsunaro R.",
                    "initial": "T.R.",
                    "last": "Chandola"
                },
                {
                    "first": "Vikash K.",
                    "initial": "V.K.",
                    "last": "Kedia"
                },
                {
                    "first": "Abhishek",
                    "initial": "A.",
                    "last": "Raut"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Flores"
                },
                {
                    "first": "Hanif",
                    "initial": "H.",
                    "last": "Shaikh"
                },
                {
                    "first": "Lalit",
                    "initial": "L.",
                    "last": "Gupta"
                },
                {
                    "first": "Rakesh",
                    "initial": "R.",
                    "last": "Patil"
                },
                {
                    "first": "Mohd",
                    "initial": "M.",
                    "last": "Aslam"
                },
                {
                    "first": "Alok",
                    "initial": "A.",
                    "last": "Arya"
                },
                {
                    "first": "Farhana",
                    "initial": "F.",
                    "last": "Rafiqi"
                },
                {
                    "first": "Subodh S.",
                    "initial": "S.S.",
                    "last": "Gupta"
                },
                {
                    "first": "Chetna H.",
                    "initial": "C.H.",
                    "last": "Maliye"
                },
                {
                    "first": "P. V.",
                    "initial": "P.V.",
                    "last": "Bahulekar"
                },
                {
                    "first": "Kiran",
                    "initial": "K.",
                    "last": "Bala"
                },
                {
                    "first": "Tajali",
                    "initial": "T.",
                    "last": "Nazir Shora"
                },
                {
                    "first": "Shahid",
                    "initial": "S.",
                    "last": "Hussain"
                },
                {
                    "first": "Mihir",
                    "initial": "M.",
                    "last": "Kumar Bhattacharya"
                },
                {
                    "first": "Ashis K.",
                    "initial": "A.K.",
                    "last": "Mukhopadhyay"
                },
                {
                    "first": "Dilip",
                    "initial": "D.",
                    "last": "Kumar Pal"
                },
                {
                    "first": "Jayanta",
                    "initial": "J.",
                    "last": "Saha"
                },
                {
                    "first": "Ranjitha S.",
                    "initial": "R.S.",
                    "last": "Shetty"
                },
                {
                    "first": "Muralidhar M.",
                    "initial": "M.M.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Chythra V.",
                    "initial": "C.V.",
                    "last": "Raj"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2017.09.014",
            "firstpage": "6228",
            "issn": "0264410X",
            "lastpage": "6237",
            "pmid": "28967523",
            "pub_year": 2017,
            "title": "A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants",
            "volume": "35"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Steele"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "De Vos"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Tumbo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Reynders"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Scholtz"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Bos"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "de Beer"
                },
                {
                    "first": "C. F.",
                    "initial": "C.F.",
                    "last": "Van der Merwe"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Delem"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.08.034",
            "firstpage": "6542",
            "issn": "0264410X",
            "lastpage": "6548",
            "pmid": "18786585",
            "pub_year": 2010,
            "title": "Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines",
            "volume": "28"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Schuster"
                },
                {
                    "first": "Juan C.",
                    "initial": "J.C.",
                    "last": "Tejedor"
                },
                {
                    "first": "Franck",
                    "initial": "F.",
                    "last": "Thollot"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Garcia-Corbeira"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Damaso"
                },
                {
                    "first": "Htay Htay",
                    "initial": "H.H.",
                    "last": "Han"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.05.057",
            "firstpage": "5272",
            "issn": "0264410X",
            "lastpage": "5279",
            "pmid": "20538094",
            "pub_year": 2010,
            "title": "Immunogenicity and safety of the human rotavirus vaccine Rotarix\u2122 co-administered with routine infant vaccines following the vaccination schedules in Europe",
            "volume": "28"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Penelope H.",
                    "initial": "P.H.",
                    "last": "Dennehy"
                },
                {
                    "first": "Helen R.",
                    "initial": "H.R.",
                    "last": "Bertrand"
                },
                {
                    "first": "Peter E.",
                    "initial": "P.E.",
                    "last": "Silas"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Damaso"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Remon",
                    "initial": "R.",
                    "last": "Abu-Elyazeed"
                }
            ],
            "doi": "10.1542/peds.2008-1059",
            "firstpage": "e1062",
            "issn": "00314005",
            "lastpage": "e1066",
            "pmid": "18977955",
            "pub_year": 2008,
            "title": "Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the united states",
            "volume": "122"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Michelle G.",
                    "initial": "M.G.",
                    "last": "Goveia"
                },
                {
                    "first": "Max",
                    "initial": "M.",
                    "last": "Ciarlet"
                },
                {
                    "first": "Katey E.",
                    "initial": "K.E.",
                    "last": "Owen"
                },
                {
                    "first": "Colette S.",
                    "initial": "C.S.",
                    "last": "Ranucci"
                }
            ],
            "doi": "10.1111/j.1749-6632.2011.05970.x",
            "firstpage": "14",
            "issn": "00778923",
            "lastpage": "18",
            "pub_year": 2011,
            "title": "Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine",
            "volume": "1222"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Manish",
                    "initial": "M.",
                    "last": "Patel"
                },
                {
                    "first": "A. Duncan",
                    "initial": "A.D.",
                    "last": "Steele"
                },
                {
                    "first": "Umesh D.",
                    "initial": "U.D.",
                    "last": "Parashar"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.11.093",
            "firstpage": "A30",
            "issn": "0264410X",
            "lastpage": "A35",
            "pmid": "22520134",
            "pub_year": 2012,
            "title": "Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines",
            "volume": "30"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Donna J.",
                    "initial": "D.J.",
                    "last": "Ing"
                },
                {
                    "first": "Roger I.",
                    "initial": "R.I.",
                    "last": "Glass"
                },
                {
                    "first": "Patricia A.",
                    "initial": "P.A.",
                    "last": "Woods"
                },
                {
                    "first": "Murri",
                    "initial": "M.",
                    "last": "Simonetti"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Pallansch"
                },
                {
                    "first": "Wallace D.",
                    "initial": "W.D.",
                    "last": "Wilcox"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Davidson"
                },
                {
                    "first": "Alan J.",
                    "initial": "A.J.",
                    "last": "Sievert"
                }
            ],
            "doi": "10.1001/archpedi.1991.02160080070023",
            "firstpage": "892",
            "issn": "0002922X",
            "lastpage": "897",
            "pmid": "1650128",
            "pub_year": 1991,
            "title": "Immunogenicity of Tetravalent Rhesus Rotavirus Vaccine Administered With Buffer and Oral Polio Vaccine",
            "volume": "145"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Devy M.",
                    "initial": "D.M.",
                    "last": "Emperador"
                },
                {
                    "first": "Daniel E.",
                    "initial": "D.E.",
                    "last": "Velasquez"
                },
                {
                    "first": "Concepcion F.",
                    "initial": "C.F.",
                    "last": "Estivariz"
                },
                {
                    "first": "Ben",
                    "initial": "B.",
                    "last": "Lopman"
                },
                {
                    "first": "Baoming",
                    "initial": "B.",
                    "last": "Jiang"
                },
                {
                    "first": "Umesh",
                    "initial": "U.",
                    "last": "Parashar"
                },
                {
                    "first": "Abhijeet",
                    "initial": "A.",
                    "last": "Anand"
                },
                {
                    "first": "Khalequ",
                    "initial": "K.",
                    "last": "Zaman"
                }
            ],
            "doi": "10.1093/cid/civ807",
            "firstpage": "150",
            "issn": "10584838",
            "lastpage": "156",
            "pmid": "26349548",
            "pub_year": 2016,
            "title": "Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh",
            "volume": "62"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Margaret B.",
                    "initial": "M.B.",
                    "last": "Rennels"
                },
                {
                    "first": "Richard L.",
                    "initial": "R.L.",
                    "last": "Ward"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Mack"
                },
                {
                    "first": "Edward T.",
                    "initial": "E.T.",
                    "last": "Zito"
                }
            ],
            "doi": "10.1093/infdis/173.2.306",
            "firstpage": "306",
            "issn": "00221899",
            "lastpage": "313",
            "pmid": "8568290",
            "pub_year": 1996,
            "title": "Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: Effects on immune responses to both vaccines and on efficacy of rotavirus vaccines",
            "volume": "173"
        },
        "b0085": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Zaman"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Fleming"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Victor"
                },
                {
                    "first": "Mohammad",
                    "initial": "M.",
                    "last": "Yunus"
                },
                {
                    "first": "Tajul Islam A.",
                    "initial": "T.I.A.",
                    "last": "Bari"
                },
                {
                    "first": "Tasnim",
                    "initial": "T.",
                    "last": "Azim"
                },
                {
                    "first": "Mustafizur",
                    "initial": "M.",
                    "last": "Rahman"
                },
                {
                    "first": "Syed Mohammad Niaz",
                    "initial": "S.M.N.",
                    "last": "Mowla"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Bellini"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "McNeal"
                },
                {
                    "first": "Joseph P.",
                    "initial": "J.P.",
                    "last": "Icenogle"
                },
                {
                    "first": "Ben",
                    "initial": "B.",
                    "last": "Lopman"
                },
                {
                    "first": "Umesh",
                    "initial": "U.",
                    "last": "Parashar"
                },
                {
                    "first": "Margaret M.",
                    "initial": "M.M.",
                    "last": "Cortese"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Duncan Steele"
                },
                {
                    "first": "Kathleen M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                }
            ],
            "doi": "10.1093/infdis/jiw024",
            "firstpage": "1686",
            "issn": "00221899",
            "lastpage": "1693",
            "pmid": "26823338",
            "pub_year": 2016,
            "title": "Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: A randomized trial",
            "volume": "213"
        },
        "b0090": null,
        "b0095": null,
        "b0100": {
            "authors": [
                {
                    "first": "Temsunaro Rongsen",
                    "initial": "T.R.",
                    "last": "Chandola"
                },
                {
                    "first": "Sunita",
                    "initial": "S.",
                    "last": "Taneja"
                },
                {
                    "first": "Nidhi",
                    "initial": "N.",
                    "last": "Goyal"
                },
                {
                    "first": "Kalpana",
                    "initial": "K.",
                    "last": "Antony"
                },
                {
                    "first": "Kiran",
                    "initial": "K.",
                    "last": "Bhatia"
                },
                {
                    "first": "Deepak",
                    "initial": "D.",
                    "last": "More"
                },
                {
                    "first": "Nita",
                    "initial": "N.",
                    "last": "Bhandari"
                },
                {
                    "first": "Iksung",
                    "initial": "I.",
                    "last": "Cho"
                },
                {
                    "first": "Krishna",
                    "initial": "K.",
                    "last": "Mohan"
                },
                {
                    "first": "Sai",
                    "initial": "S.",
                    "last": "Prasad"
                },
                {
                    "first": "G. V.J.A.",
                    "initial": "G.V.J.A.",
                    "last": "Harshavardhan"
                },
                {
                    "first": "Tataji Surender",
                    "initial": "T.S.",
                    "last": "Rao"
                },
                {
                    "first": "Sudhanshu",
                    "initial": "S.",
                    "last": "Vrati"
                },
                {
                    "first": "Maharaj Kishan",
                    "initial": "M.K.",
                    "last": "Bhan"
                }
            ],
            "doi": "10.1016/j.heliyon.2017.e00302",
            "issn": "24058440",
            "pub_year": 2017,
            "title": "ROTAVAC\u00ae does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial",
            "volume": "3"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Roland W.",
                    "initial": "R.W.",
                    "last": "Sutter"
                },
                {
                    "first": "T. Jacob",
                    "initial": "T.J.",
                    "last": "John"
                },
                {
                    "first": "Hemant",
                    "initial": "H.",
                    "last": "Jain"
                },
                {
                    "first": "Sharad",
                    "initial": "S.",
                    "last": "Agarkhedkar"
                },
                {
                    "first": "Padmasani Venkat",
                    "initial": "P.V.",
                    "last": "Ramanan"
                },
                {
                    "first": "Harish",
                    "initial": "H.",
                    "last": "Verma"
                },
                {
                    "first": "Jagadish",
                    "initial": "J.",
                    "last": "Deshpande"
                },
                {
                    "first": "Ajit Pal",
                    "initial": "A.P.",
                    "last": "Singh"
                },
                {
                    "first": "Meghana",
                    "initial": "M.",
                    "last": "Sreevatsava"
                },
                {
                    "first": "Pradeep",
                    "initial": "P.",
                    "last": "Malankar"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Burton"
                },
                {
                    "first": "Arani",
                    "initial": "A.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Hamid",
                    "initial": "H.",
                    "last": "Jafari"
                },
                {
                    "first": "R. Bruce",
                    "initial": "R.B.",
                    "last": "Aylward"
                }
            ],
            "doi": "10.1016/S0140-6736(10)61230-5",
            "firstpage": "1682",
            "issn": "01406736",
            "lastpage": "1688",
            "pmid": "20980048",
            "pub_year": 2010,
            "title": "Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial",
            "volume": "376"
        },
        "b0110": null,
        "b0115": null
    },
    "body_text": [
        {
            "endOffset": 11476,
            "parents": [],
            "secId": "s0005",
            "sentence": "Like other live oral rotavirus vaccines, BRV-PV is indicated for routine infant immunization with a three-dose schedule at 6, 10, and 14 weeks of age.",
            "startOffset": 11326,
            "title": "Introduction"
        },
        {
            "endOffset": 21816,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "For all other antibodies too, the GMC ratios for the combined BRV-PV/Rotarix\u00ae group were around 1.",
            "startOffset": 21718,
            "title": "GMC/GMT results"
        },
        {
            "endOffset": 15185,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "bOPV (BioPolio\u00ae, Bharat Biotech International Ltd., India) was also given orally.",
            "startOffset": 15104,
            "title": "Investigational products"
        },
        {
            "endOffset": 16902,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Commercial ELISA kits of Virion - Serion (diphtheria, pertussis, and tetanus), Binding site (Hib), and Vitros (hepatitis B) were used for antibody measurements.",
            "startOffset": 16742,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 11326,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 11325,
                    "startOffset": 11320
                },
                "b0020": {
                    "endOffset": 11325,
                    "startOffset": 11320
                },
                "b0025": {
                    "endOffset": 11325,
                    "startOffset": 11320
                },
                "b0030": {
                    "endOffset": 11325,
                    "startOffset": 11320
                }
            },
            "secId": "s0005",
            "sentence": "The vaccine has shown satisfactory clinical performance in various studies and has an added feature of heat stability [3\u20136].",
            "startOffset": 11202,
            "title": "Introduction"
        },
        {
            "endOffset": 14110,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "BRV-PV is a live attenuated, pentavalent, human-bovine reassortant rotavirus vaccine (ROTASIIL\u00ae, Serum Institute of India Pvt. Ltd., SIIPL).",
            "startOffset": 13970,
            "title": "Investigational products"
        },
        {
            "endOffset": 17808,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The PP population was the primary analysis population for all immunogenicity objectives, while the FA population results were supportive.",
            "startOffset": 17671,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23582,
            "parents": [],
            "secId": "s0070",
            "sentence": "A similar phase III study in India assessed whether ROTAVAC\u00ae interfered with the immune response to OPV and DTwP-HepB-Hib vaccines.",
            "startOffset": 23451,
            "title": "Discussion"
        },
        {
            "endOffset": 14531,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "DTwP-HepB-Hib vaccine (Pentavac\u00ae PFS, SIIPL, Batch No. 137K5001A, Expiry December 2016) was given by intramuscular injection.",
            "startOffset": 14406,
            "title": "Investigational products"
        },
        {
            "endOffset": 18627,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Non-inferiority for pertussis was examined using the ratio of GMCs (combined BRV groups and Rotarix\u00ae) with a non-inferiority criterion that the lower limit of the two-sided 90% CI for the ratio is >0.5.",
            "startOffset": 18425,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19233,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "At this size, this study provided >99.9% power for testing potential interference for all of the UIP vaccines.",
            "startOffset": 19123,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Four weeks after the third dose, a single blood sample was collected from each child.",
            "startOffset": 16322,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 25436,
            "parents": [],
            "secId": "s0080",
            "sentence": "The study was funded by PATH and SIIPL.",
            "startOffset": 25397,
            "title": "Funding"
        },
        {
            "endOffset": 12906,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The study subjects (n = 1,500) were equally randomized to four arms with 375 subjects each; three received different lots of BRV-PV and one received Rotarix\u00ae.",
            "startOffset": 12748,
            "title": "Study design"
        },
        {
            "endOffset": 16155,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A block size of 12 was used to ensure a 1:1:1:1 balance for the study.",
            "startOffset": 16085,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 12554,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study conduct was in compliance with the Declaration of Helsinki and good clinical practices guidelines.",
            "startOffset": 12446,
            "title": "Ethics"
        },
        {
            "endOffset": 14406,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The vaccine used in the study was a lyophilized vaccine to be reconstituted with a liquid diluent in a pre-filled oral applicator.",
            "startOffset": 14276,
            "title": "Investigational products"
        },
        {
            "endOffset": 24758,
            "parents": [],
            "secId": "s0070",
            "sentence": "All participants had received a birth dose of OPV as it is part of the UIP in India.",
            "startOffset": 24674,
            "title": "Discussion"
        },
        {
            "endOffset": 20129,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "24.73% of subjects received tOPV, 42.93% received bOPV, and 32.13% received a combination of tOPV and bOPV concomitantly with BRV-PV and Rotarix\u00ae/placebo doses.",
            "startOffset": 19969,
            "title": "Data on vaccines used"
        },
        {
            "endOffset": 25225,
            "parents": [],
            "secId": "s0070",
            "sentence": "To conclude, BRV-PV does not interfere with immune response of UIP vaccines.",
            "startOffset": 25149,
            "title": "Discussion"
        },
        {
            "endOffset": 14190,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 14189,
                    "startOffset": 14186
                }
            },
            "secId": "s0030",
            "sentence": "It is available as a lyophilized powder along with 2.5 ml buffered diluent [4].",
            "startOffset": 14111,
            "title": "Investigational products"
        },
        {
            "endOffset": 21308,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For both type 1 and type 3 antibodies, seroprotection rates were more than 98% in both the groups, irrespective of whether they received tOPV alone, bOPV alone or mixed schedules (Table 3).",
            "startOffset": 21119,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 19122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The sample size calculation was driven by the lot-to-lot consistency objective, which required an evaluable sample size of 900 subjects for the BRV-PV lots combined and 300 subjects for the Rotarix\u00ae group.",
            "startOffset": 18917,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 17953,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "All statistical analyses were conducted using SAS\u00ae software.",
            "startOffset": 17893,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 13943,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Significant malnutrition or any systemic disorder, congenital abdominal disorders, intussusception, abdominal surgery, impairment of immunological function, persistent diarrhea, or allergy to any components of the study vaccines were exclusion criteria.",
            "startOffset": 13690,
            "title": "Selection criteria"
        },
        {
            "endOffset": 22344,
            "parents": [],
            "secId": "s0070",
            "sentence": "BRV-PV did not interfere with the immunogenicity of any of the antigens, as assessed by both seroprotection rates and GMT ratios.",
            "startOffset": 22215,
            "title": "Discussion"
        },
        {
            "endOffset": 23675,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 23674,
                    "startOffset": 23670
                }
            },
            "secId": "s0070",
            "sentence": "Like ours, that study found no interference with the immune response to those vaccines [20].",
            "startOffset": 23583,
            "title": "Discussion"
        },
        {
            "endOffset": 25390,
            "parents": [],
            "secId": "s0075",
            "sentence": "Dr. Prasad S. Kulkarni, Dr. Sajjad Desai, Dr. Bhagwat Gunale, and Mr. AbhijeetDharmadhikari are employed by SIIPL, which manufactures the BRV-PV.",
            "startOffset": 25245,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 13206,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "As per the Universal Immunisation Programme (UIP) in India, the subjects also received three doses each of DTwP-HepB-Hib and oral polio vaccine (OPV) at 6, 10, and 14 weeks of age.",
            "startOffset": 13026,
            "title": "Study design"
        },
        {
            "endOffset": 19323,
            "parents": [],
            "secId": "s0050",
            "sentence": "A total of 1585 subjects were screened and 1500 eligible subjects were randomized.",
            "startOffset": 19241,
            "title": "Results"
        },
        {
            "endOffset": 23194,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 23193,
                    "startOffset": 23189
                }
            },
            "secId": "s0070",
            "sentence": "A booster dose of Rotarix given simultaneously with measles-rubella vaccine did not have an impact on the immunogenicity of any of the two vaccines (measles or rubella) [17].",
            "startOffset": 23020,
            "title": "Discussion"
        },
        {
            "endOffset": 15920,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "BRV-PV, Rotarix\u00ae, DTwP-HepB-Hib, and IPV vaccines were stored at 2\u20138 \u00b0C, while both bOPV and tOPV were stored at \u2264\u221220 \u00b0C.",
            "startOffset": 15799,
            "title": "Investigational products"
        },
        {
            "endOffset": 16741,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "IgG antibodies against diphtheria, pertussis, tetanus, Hib, and hepatitis B were tested at Quest Diagnostics India Private Limited, Gurgaon.",
            "startOffset": 16601,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 24674,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 24604,
                    "startOffset": 24601
                },
                "b0110": {
                    "endOffset": 24673,
                    "startOffset": 24669
                }
            },
            "secId": "s0070",
            "sentence": "We used Rotarix as a control, rather than placebo because it is not ethically possible to keep a group of infants which receives no rotavirus vaccine, especially because WHO recommends rotavirus vaccination for all the infants [2] and because India has included rotavirus vaccination in the UIP [22].",
            "startOffset": 24374,
            "title": "Discussion"
        },
        {
            "endOffset": 19969,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "All subjects also received IPV at the age of 14 weeks.",
            "startOffset": 19915,
            "title": "Data on vaccines used"
        },
        {
            "endOffset": 15799,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Each 0.5 ml dose contains not less than inactivated poliovirus type 1, Mahoney strain 40 D antigen units, poliovirus type 2, MEF-I strain 8 D antigen units, and poliovirus type 3, Saukett strain 32 D antigen units.",
            "startOffset": 15585,
            "title": "Investigational products"
        },
        {
            "endOffset": 22747,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 22746,
                    "startOffset": 22742
                }
            },
            "secId": "s0070",
            "sentence": "Several studies have pointed out to some interference of OPV with the responses to rotavirus vaccines, mostly after the first dose [15].",
            "startOffset": 22611,
            "title": "Discussion"
        },
        {
            "endOffset": 25148,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our results are thus in line with studies of all previously licensed rotavirus vaccines.",
            "startOffset": 25060,
            "title": "Discussion"
        },
        {
            "endOffset": 20278,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "UIP vaccines elicited high immunogenicity with most of the subjects achieving seroprotective antibody levels.",
            "startOffset": 20169,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 25060,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 25059,
                    "startOffset": 25055
                }
            },
            "secId": "s0070",
            "sentence": "This was as per WHO\u2019s polio endgame strategy which included a global switch from tOPV to bOPV and addition of a single dose of IPV in EPI schedules in countries using OPV [23].",
            "startOffset": 24884,
            "title": "Discussion"
        },
        {
            "endOffset": 16294,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "While the study was not blinded to the clinical staff or the parents, the laboratory personnel were not aware of the treatment allocation.",
            "startOffset": 16156,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 12609,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Identity of participants was always kept confidential.",
            "startOffset": 12555,
            "title": "Ethics"
        },
        {
            "endOffset": 15317,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Two batches (Batch No. 68CV00416008, Expiry December 2017 and Batch No. 68CV00716014, Expiry February 2018) were used in the study.",
            "startOffset": 15186,
            "title": "Investigational products"
        },
        {
            "endOffset": 11794,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 11793,
                    "startOffset": 11790
                }
            },
            "secId": "s0005",
            "sentence": "As per regulatory requirements, it has to be demonstrated that any new vaccine does not interfere with the immune responses to these vaccines [7].",
            "startOffset": 11648,
            "title": "Introduction"
        },
        {
            "endOffset": 17256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Seropositivity for pertussis was defined as concentration of >50 IU/ml, as per the manufacturer\u2019s instructions.",
            "startOffset": 17145,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 11647,
            "parents": [],
            "secId": "s0005",
            "sentence": "For the last many years, vaccines against diphtheria, pertussis, tetanus, hepatitis B, haemophilus influenzae type b, and polio have also been given at these time points.",
            "startOffset": 11477,
            "title": "Introduction"
        },
        {
            "endOffset": 18179,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Non-inferiority for polio type 1, polio type 3, diphtheria, tetanus, Hib, and hepatitis B was evaluated using the two-sided 90% CI for the difference between seroprotection rates in the combined BRV-PV lots and Rotarix\u00ae group.",
            "startOffset": 17953,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24127,
            "parents": [],
            "secId": "s0070",
            "sentence": "Though we did not find any interference by BRV-PV with polio vaccines irrespective of the type of OPV used, the switch gave us an opportunity to compare immunogenicity of tOPV, bOPV and mixed schedules.",
            "startOffset": 23925,
            "title": "Discussion"
        },
        {
            "endOffset": 24883,
            "parents": [],
            "secId": "s0070",
            "sentence": "They also received three doses OPV (initially trivalent and bivalent after April 2016) and one dose of IPV during the study.",
            "startOffset": 24759,
            "title": "Discussion"
        },
        {
            "endOffset": 21973,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Though statistically not compared, the GMTs for both type 1 and type 3 polioviruses were higher with bOPV alone as compared to tOPV alone in both the groups.",
            "startOffset": 21816,
            "title": "GMC/GMT results"
        },
        {
            "endOffset": 13025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Three doses of BRV-PV or two doses of Rotarix\u00ae and one dose of placebo were administered at 6, 10, and 14 weeks of age.",
            "startOffset": 12906,
            "title": "Study design"
        },
        {
            "endOffset": 18917,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The mean difference and the corresponding 90% CI limits were exponentiated to obtain the GMC ratio and its 90% CI.",
            "startOffset": 18803,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23924,
            "parents": [],
            "secId": "s0070",
            "sentence": "It should be noted, that in our study, both OPV and IPV were received by all children since mid-way through the study, since the Ministry of Health, Government of India switched tOPV to bOPV and IPV was used to fill the gap between the two vaccines.",
            "startOffset": 23675,
            "title": "Discussion"
        },
        {
            "endOffset": 22610,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 22609,
                    "startOffset": 22605
                }
            },
            "secId": "s0070",
            "sentence": "Further, co-administration of Rotarix with conjugate pneumococcal vaccine have also shown no interference [11].",
            "startOffset": 22499,
            "title": "Discussion"
        },
        {
            "endOffset": 12747,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "This Phase III multicentre, open-label, randomized, controlled study was conducted between December 2015 and November 2016.",
            "startOffset": 12624,
            "title": "Study design"
        },
        {
            "endOffset": 20873,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For Hib, 100% short term seroprotection (\u22650.15 mcg/mL) was seen in both treatment groups.",
            "startOffset": 20784,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 21406,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Thus, BRV-PV did not interfere with OPV, irrespective of the type of OPV received (bOPV or tOPV).",
            "startOffset": 21309,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 18425,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Non-inferiority was declared if lower limits of the two-sided 90% CI for the difference (BRV lots combined, Rotarix\u00ae reference) was >\u221210.0% for the above six antibodies.",
            "startOffset": 18256,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 11065,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 10965,
                    "startOffset": 10962
                },
                "b0010": {
                    "endOffset": 11064,
                    "startOffset": 11061
                }
            },
            "secId": "s0005",
            "sentence": "Considering that rotavirus gastroenteritis is a significant public health problem, especially in low-resource countries [1], the World Health Organization (WHO) recommends universal immunization with rotavirus vaccines [2].",
            "startOffset": 10842,
            "title": "Introduction"
        },
        {
            "endOffset": 20784,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Non-inferiority was demonstrated, as the lower limit of the two-sided 90% CI for the rate difference for all the antibodies was >\u221210.0% (Table 1).",
            "startOffset": 20638,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 19642,
            "parents": [],
            "secId": "s0050",
            "sentence": "The details of the exclusions and the demographic data are given in the lot-to-lot consistency publication (Under publication).",
            "startOffset": 19515,
            "title": "Results"
        },
        {
            "endOffset": 13469,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 13468,
                    "startOffset": 13465
                }
            },
            "secId": "s0020",
            "sentence": "Trivalent OPV (tOPV) and bivalent OPV (bOPV) were given to subjects before and after 25 April 2016, respectively, in accordance with the global switch mandated by WHO [8].",
            "startOffset": 13298,
            "title": "Study design"
        },
        {
            "endOffset": 16600,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Neutralizing antibody titers \u22651:8 were considered seroprotective.",
            "startOffset": 16535,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 13616,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The subjects were healthy infants of 6\u20138 weeks of age at the time of enrolment who had received HepB vaccine and OPV at birth.",
            "startOffset": 13490,
            "title": "Selection criteria"
        },
        {
            "endOffset": 19855,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "84 (5.6%) subjects received only one dose, 19 (1.27%) received two doses, and 1394 (92.93%) received all three doses of rotavirus vaccines.",
            "startOffset": 19716,
            "title": "Data on vaccines used"
        },
        {
            "endOffset": 12005,
            "parents": [],
            "secId": "s0005",
            "sentence": "The present study was undertaken with two primary objectives: (a) to demonstrate clinical lot-to-lot consistency of BRV-PV and (b) to demonstrate non-interference in the immune responses of concomitant vaccines.",
            "startOffset": 11794,
            "title": "Introduction"
        },
        {
            "endOffset": 20468,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For all other antigens, seroprotection was seen in >99% subjects in both groups (Table 1).",
            "startOffset": 20378,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 22115,
            "parents": [],
            "secId": "s0070",
            "sentence": "In this Phase III study we evaluated the potential interference of SIIPL's BRV-PV with routine UIP vaccinations in healthy infants.",
            "startOffset": 21984,
            "title": "Discussion"
        },
        {
            "endOffset": 11201,
            "parents": [],
            "secId": "s0005",
            "sentence": "To meet the global demand, a bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV, ROTASIIL\u00ae) was recently launched in India.",
            "startOffset": 11066,
            "title": "Introduction"
        },
        {
            "endOffset": 15584,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "One dose of IPV (Poliovac PFS\u00ae, SIIPL, Batch No. 151K5006A, Expiry March 2017) was given intramuscularly.",
            "startOffset": 15479,
            "title": "Investigational products"
        },
        {
            "endOffset": 22498,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 22459,
                    "startOffset": 22453
                },
                "b0050": {
                    "endOffset": 22459,
                    "startOffset": 22453
                },
                "b0055": {
                    "endOffset": 22459,
                    "startOffset": 22453
                },
                "b0060": {
                    "endOffset": 22476,
                    "startOffset": 22469
                },
                "b0065": {
                    "endOffset": 22476,
                    "startOffset": 22469
                },
                "b0070": {
                    "endOffset": 22497,
                    "startOffset": 22493
                }
            },
            "secId": "s0070",
            "sentence": "No interference by parenteral vaccines like DTP, HepB and Hib has been observed in several trials of Rotarix [9\u201311], RotaTeq [12,13] and Rotashield, [14].",
            "startOffset": 22344,
            "title": "Discussion"
        },
        {
            "endOffset": 12353,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was approved by the institutional ethics committees and the Indian regulatory authorities.",
            "startOffset": 12253,
            "title": "Ethics"
        },
        {
            "endOffset": 19692,
            "parents": [],
            "secId": "s0050",
            "sentence": "The results from the PP population are presented.",
            "startOffset": 19643,
            "title": "Results"
        },
        {
            "endOffset": 13297,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In addition, the subjects received inactivated polio vaccine (IPV) at the age of 14 weeks.",
            "startOffset": 13207,
            "title": "Study design"
        },
        {
            "endOffset": 18255,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The two sided 90% CIs were obtained using the Newcombe hybrid score method.",
            "startOffset": 18180,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 22911,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 22910,
                    "startOffset": 22901
                },
                "b0050": {
                    "endOffset": 22910,
                    "startOffset": 22901
                },
                "b0080": {
                    "endOffset": 22910,
                    "startOffset": 22901
                }
            },
            "secId": "s0070",
            "sentence": "Subsequent doses have resulted in no significant changes in the overall responses to the rotavirus component and clinical protection has been maintained [9,10,16].",
            "startOffset": 22748,
            "title": "Discussion"
        },
        {
            "endOffset": 20377,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "More than 97% of the subjects presented seroprotective antibody titres against Hib in both groups.",
            "startOffset": 20279,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 21006,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Pertussis seropositivity rates were similar (around 66%) in both the groups, with a difference of 0.11% [CI: \u22124.73; 5.14] (Table 1).",
            "startOffset": 20874,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 17670,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The per-protocol (PP) population included all subjects in the FA population who had received all three doses of study vaccines as per the assigned group with no major protocol violations.",
            "startOffset": 17483,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16994,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The kits used for testing were validated by the manufacturers as well as by the laboratory.",
            "startOffset": 16903,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 23451,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 23249,
                    "startOffset": 23242
                },
                "b0095": {
                    "endOffset": 23249,
                    "startOffset": 23242
                }
            },
            "secId": "s0070",
            "sentence": "As per their summary of product characteristics [18,19] and the studies quoted above, Rotarix and Rotateq do not interfere with the immune response of DTPa, HepB, IPV, Hib, pneumococcal conjugate vaccine, meningococcal serogroup C conjugate vaccine and OPV.",
            "startOffset": 23194,
            "title": "Discussion"
        },
        {
            "endOffset": 22214,
            "parents": [],
            "secId": "s0070",
            "sentence": "We found that all UIP vaccines elicited high immunogenicity in the great majority of the subjects.",
            "startOffset": 22116,
            "title": "Discussion"
        },
        {
            "endOffset": 23019,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 23018,
                    "startOffset": 23014
                }
            },
            "secId": "s0070",
            "sentence": "No study has detected interference by rotavirus vaccine on the seroconversion or seroprotection of OPV [13].",
            "startOffset": 22911,
            "title": "Discussion"
        },
        {
            "endOffset": 21118,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The percentage of subjects with polio-seroprotective titers according to type of OPV received was also assessed.",
            "startOffset": 21006,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 14772,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Each 0.5 ml dose of Pentavac\u00ae PFS contains: diphtheria toxoid \u226425 Lf (\u226530 IU), tetanus toxoid \u22652.5 Lf (\u226540 IU), B. pertussis (whole cell) \u226416 OU (\u22654 IU), HBsAg (rDNA) \u226510 \u00b5g, and Hib polysaccharide (PRP) conjugated to tetanus toxoid 10 mcg.",
            "startOffset": 14532,
            "title": "Investigational products"
        },
        {
            "endOffset": 21717,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Thus, the lower limit of the 90% CI for the GMCs ratio was >0.5, which supports the non-inferiority hypothesis that the BRV-PV vaccine does not interfere with pertussis vaccination.",
            "startOffset": 21536,
            "title": "GMC/GMT results"
        },
        {
            "endOffset": 19914,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "All subjects received DTwP-HepB-Hib and OPV concomitantly.",
            "startOffset": 19856,
            "title": "Data on vaccines used"
        },
        {
            "endOffset": 12445,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Parent(s) gave a written informed consent for participation of their children in the study.",
            "startOffset": 12354,
            "title": "Ethics"
        },
        {
            "endOffset": 21535,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The ratio of anti-pertussis GMC for the combined BRV-PV/Rotarix\u00ae group was 1.04 [90% CI: 0.90; 1.19] (Table 2).",
            "startOffset": 21424,
            "title": "GMC/GMT results"
        },
        {
            "endOffset": 12123,
            "parents": [],
            "secId": "s0005",
            "sentence": "The results of safety, rotavirus vaccine immunogenicity, and lot-to-lot consistency are under publication separately.",
            "startOffset": 12006,
            "title": "Introduction"
        },
        {
            "endOffset": 19514,
            "parents": [],
            "secId": "s0050",
            "sentence": "Of these, 33 subjects had a major protocol violation; therefore, 1341 subjects were part of the PP population.",
            "startOffset": 19404,
            "title": "Results"
        },
        {
            "endOffset": 20637,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The difference in seroprotection rates for different antibodies between BRV-PV and Rotarix\u00ae groups ranged from \u22120.59 [90% CI: \u22121.27; 0.52] to 0.62 [90% CI: \u22120.09; 1.99].",
            "startOffset": 20468,
            "title": "Seroprotection/seropositivity results"
        },
        {
            "endOffset": 16534,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Polio type 1 and type 3 antibodies were tested by a validated neutralization assay at the Enterovirus Research Centre, Mumbai.",
            "startOffset": 16408,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 13689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Infants with any acute disease were temporarily excluded from enrolment.",
            "startOffset": 13617,
            "title": "Selection criteria"
        },
        {
            "endOffset": 14889,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "tOPV (BioPolio\u00ae, Bharat Biotech International Ltd., India, Batch No. 63AS15001, Expiry August 2017) was given orally.",
            "startOffset": 14772,
            "title": "Investigational products"
        },
        {
            "endOffset": 17892,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "A one-sided type I error rate of 0.05 was used for the non-inferiority comparisons.",
            "startOffset": 17809,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19403,
            "parents": [],
            "secId": "s0050",
            "sentence": "Of these, 1374 subjects completed the study and were part of the FA population.",
            "startOffset": 19324,
            "title": "Results"
        },
        {
            "endOffset": 24374,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 24373,
                    "startOffset": 24369
                }
            },
            "secId": "s0070",
            "sentence": "Similarly, a study in India had found lower GMTs as well as lower seroconversion rates with tOPV as compared to bOPV [21].",
            "startOffset": 24252,
            "title": "Discussion"
        },
        {
            "endOffset": 15104,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Each dose of two drops (0.1 ml) contains not less than 106.0 CCID50 infectious units of type 1 poliovirus, 105.0 CCID50 infectious units of type 2 poliovirus, and 105.8 CCID50 infectious units of type 3 poliovirus.",
            "startOffset": 14890,
            "title": "Investigational products"
        },
        {
            "endOffset": 17144,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Antibody concentrations \u22650.1 IU/mL (for diphtheria and tetanus), \u22651 mcg/mL (for Hib) and \u226510 mIU/mL (for hepatitis B) were considered seroprotective.",
            "startOffset": 16995,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 17482,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The full analysis (FA) population included all subjects in the enrolled population who were randomized and received at least one dose of study vaccination and had post-vaccination immunogenicity results.",
            "startOffset": 17279,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 14275,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Rotarix\u00ae (GlaxoSmithKline plc, Belgium) is also a live attenuated rotavirus vaccine.",
            "startOffset": 14191,
            "title": "Investigational products"
        },
        {
            "endOffset": 24251,
            "parents": [],
            "secId": "s0070",
            "sentence": "The seroprotection rates were high (>98%) with both the vaccines but the GMTs appeared lower with tOPV as compared to bOPV.",
            "startOffset": 24128,
            "title": "Discussion"
        },
        {
            "endOffset": 15479,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Each dose of two drops (0.1 ml) contains not less than 106.0 CCID50 infectious units of type 1 poliovirus and 105.8 CCID50 infectious units of type 3 poliovirus.",
            "startOffset": 15318,
            "title": "Investigational products"
        },
        {
            "endOffset": 12236,
            "parents": [],
            "secId": "s0005",
            "sentence": "The present paper provides the findings on the non-interference with the immunogenicity of concomitant vaccines.",
            "startOffset": 12124,
            "title": "Introduction"
        },
        {
            "endOffset": 16084,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The eligible subjects were randomized to three BRV-PV groups or to Rotarix\u00ae group according to a computer-generated randomization list.",
            "startOffset": 15949,
            "title": "Randomization and blinding"
        },
        {
            "endOffset": 18802,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The log10-transformed concentrations were used to construct a 90% CI for the ratio using t-distribution for the mean difference between the combined BRV and reference groups.",
            "startOffset": 18628,
            "title": "Statistical analysis"
        }
    ],
    "docId": "S0264410X18310739",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Sajjad",
                "initial": "S.",
                "last": "Desai"
            },
            {
                "email": null,
                "first": "Niraj",
                "initial": "N.",
                "last": "Rathi"
            },
            {
                "email": null,
                "first": "Anand",
                "initial": "A.",
                "last": "Kawade"
            },
            {
                "email": null,
                "first": "Padmasani",
                "initial": "P.",
                "last": "Venkatramanan"
            },
            {
                "email": null,
                "first": "Ritabrata",
                "initial": "R.",
                "last": "Kundu"
            },
            {
                "email": null,
                "first": "Sanjay K.",
                "initial": "S.K.",
                "last": "Lalwani"
            },
            {
                "email": null,
                "first": "A. P.",
                "initial": "A.P.",
                "last": "Dubey"
            },
            {
                "email": null,
                "first": "J.",
                "initial": "J.",
                "last": "Venkateswara Rao"
            },
            {
                "email": null,
                "first": "D.",
                "initial": "D.",
                "last": "Narayanappa"
            },
            {
                "email": null,
                "first": "Radha",
                "initial": "R.",
                "last": "Ghildiyal"
            },
            {
                "email": null,
                "first": "Nithya J.",
                "initial": "N.J.",
                "last": "Gogtay"
            },
            {
                "email": null,
                "first": "P.",
                "initial": "P.",
                "last": "Venugopal"
            },
            {
                "email": null,
                "first": "Sonali",
                "initial": "S.",
                "last": "Palkar"
            },
            {
                "email": null,
                "first": "Renuka",
                "initial": "R.",
                "last": "Munshi"
            },
            {
                "email": null,
                "first": "Ashish",
                "initial": "A.",
                "last": "Bavdekar"
            },
            {
                "email": null,
                "first": "Sanjay",
                "initial": "S.",
                "last": "Juvekar"
            },
            {
                "email": null,
                "first": "Nupur",
                "initial": "N.",
                "last": "Ganguly"
            },
            {
                "email": null,
                "first": "Prabal",
                "initial": "P.",
                "last": "Niyogi"
            },
            {
                "email": null,
                "first": "Kheya Ghosh",
                "initial": "K.G.",
                "last": "Uttam"
            },
            {
                "email": null,
                "first": "Alpana",
                "initial": "A.",
                "last": "Kondekar"
            },
            {
                "email": null,
                "first": "Dipti",
                "initial": "D.",
                "last": "Kumbhar"
            },
            {
                "email": null,
                "first": "Smilu",
                "initial": "S.",
                "last": "Mohanlal"
            },
            {
                "email": null,
                "first": "Mukesh C.",
                "initial": "M.C.",
                "last": "Agarwal"
            },
            {
                "email": null,
                "first": "Parvan",
                "initial": "P.",
                "last": "Shetty"
            },
            {
                "email": null,
                "first": "Kalpana",
                "initial": "K.",
                "last": "Antony"
            },
            {
                "email": null,
                "first": "Bhagwat",
                "initial": "B.",
                "last": "Gunale"
            },
            {
                "email": null,
                "first": "Abhijeet",
                "initial": "A.",
                "last": "Dharmadhikari"
            },
            {
                "email": null,
                "first": "Jagdish",
                "initial": "J.",
                "last": "Deshpande"
            },
            {
                "email": null,
                "first": "Uma",
                "initial": "U.",
                "last": "Nalavade"
            },
            {
                "email": null,
                "first": "Deepa",
                "initial": "D.",
                "last": "Sharma"
            },
            {
                "email": null,
                "first": "Anurag",
                "initial": "A.",
                "last": "Bansal"
            },
            {
                "email": null,
                "first": "Yuxiao",
                "initial": "Y.",
                "last": "Tang"
            },
            {
                "email": null,
                "first": "Jorge",
                "initial": "J.",
                "last": "Flores"
            },
            {
                "email": "drpsk@seruminstitute.com",
                "first": "Prasad S.",
                "initial": "P.S.",
                "last": "Kulkarni"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.07.064",
        "firstpage": "5519",
        "issn": "0264410X",
        "keywords": [
            "Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV)",
            "DTwP-HepB-Hib vaccine",
            "Immune response",
            "Interference",
            "Oral polio vaccine (OPV)"
        ],
        "lastpage": "5523",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL\u00ae with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine"
    }
}